Israeli scientist: Two-thirds of the way toward COVID-19 vaccine

Gershoni, who was recently granted a patent by the United States Patent and Trademark Office for his vaccine design for the coronavirus – after studying the family of viruses for 15 years – explained that the vaccine intends to target the virus's Receptor Binding Motif (RBM), a critical weak point which allows the virus to attach itself and infect a target cell. The Jerusalem Post